FDA places hold on Halozyme's PEGPH20 pancreatic cancer study
This article was originally published in Scrip
Executive Summary
Investors appeared prepared on 9 April for the revelation from Halozyme Therapeutics the FDA had indeed placed a clinical hold on the company's Phase II trial of PEGPH20 in patients with pancreatic cancer after the company last week said it was voluntarily halting the trial.